Royalty Pharma plc
RPRX
$53.25
$1.553.00%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 23.12% | 2.88% | -47.02% | -70.42% | 4,909.40% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | 45.24% | 42.14% | 46.67% | 74.82% | 21.43% |
| Total Other Non-Cash Items | -1.61% | -20.15% | 31.10% | -169.21% | -590.35% |
| Change in Net Operating Assets | 9.14% | 16.36% | 7.58% | 7.89% | 6.96% |
| Cash from Operations | 20.49% | 11.40% | -0.14% | -44.70% | -10.32% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -194.83% | -67.69% | 19.67% | 73.38% | 681.55% |
| Cash from Investing | -194.83% | -67.69% | 19.65% | 65.07% | 681.55% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | 92.93% | -53.09% | -50.95% | -264.47% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -9.58% | -0.73% | -1.33% | 1.79% | -1.65% |
| Other Financing Activities | 13.91% | -11.65% | -11.56% | 11.94% | -16.05% |
| Cash from Financing | 71.03% | -16.14% | 272.88% | -143.91% | -344.01% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -120.35% | -1,423.10% | 137.69% | -149.46% | -56.64% |